Tags : AERISTO P-IIIb

Pharma

AstraZeneca announces Results of AERISTO P-IIIb trial for Bevespi Aerosphere

Shots: The AERISTO study recruited 1,119 patients receiving either Bevespi Aerosphere (7.2/4.8µg) BID via pressurized metered-dose inhaler or umeclidinium/vilanterol (62.5/25µg) QD via dry powder inhaler Another P-III PINNACLE study enrolled ~5,000 patients and is performed to test safety and efficacy of Bevespi Aerosphere vs. umeclidinium/vilanterol  Bevespi Aerosphere (glycopyrronium/formoterol fumarate) is approved in the US and […]Read More